29.76

1.05% 0.34

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Why IMVT Down? Discussions Forecast

Immunovant Inc stock is traded at $29.76, with a volume of 301.17K. It is up +1.05% in the last 24 hours and down -2.56% over the past month. Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Previous Close:

$29.42

Open:

$29.17

24h Volume:

301.17K

Relative Volume:

0.36

Market Cap:

$4.23B

Revenue:

Net Income/Loss:

$-272.55M

P/E Ratio:

-15.42

EPS:

-1.93

Net Cash Flow:

$-243.55M

1W Performance:

-0.50%

1M Performance:

-2.56%

6M Performance:

+3.01%

1Y Performance:

-12.53%

1-Day Range:

$28.45

$29.86

1-Week Range:

$28.28

$30.30

52-Week Range:

$24.67

$45.58

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

917-580-3099

Address

320 WEST 37TH STREET, NEW YORK, NY

Employee

207

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMVT's Discussions on Twitter

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Nov 04, 2024

Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Nov 04, 2024

Nov 02, 2024

Where are the Opportunities in (IMVT) - Stock Traders Daily

Nov 02, 2024

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World

Nov 02, 2024

Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat

Nov 02, 2024

Oct 30, 2024

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat

Oct 30, 2024

Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times

Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com

Oct 29, 2024

Oct 26, 2024

Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada

Oct 26, 2024

Oct 25, 2024

Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada

Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia

Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com

Oct 25, 2024

Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia

Oct 19, 2024

Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India

Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia

Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock - Investing.com India

Oct 19, 2024

Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com

Oct 19, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia

Oct 19, 2024

Oct 18, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com

Oct 18, 2024

Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat

Oct 18, 2024

Oct 16, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 16, 2024

IMVT (Immunovant Inc) has impressive results - US Post News

Oct 16, 2024

Oct 15, 2024

Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily

Oct 15, 2024

Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex

Oct 15, 2024

Oct 14, 2024

Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha

Oct 14, 2024

The Manufacturers Life Insurance Company Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Oct 14, 2024

Oct 12, 2024

Immunovant CEO sells over $131k in company stock By Investing.com - Investing.com Australia

Oct 12, 2024

Immunovant CFO sells over $150k in company stock By Investing.com - Investing.com Australia

Oct 12, 2024

Oct 11, 2024